Stockscreener 앱 받기
20.09
2.33%
-0.48
전일 마감가:
$20.57
열려 있는:
$20.63
하루 거래량:
167.74K
Relative Volume:
0.71
시가총액:
$409.04M
수익:
$71.10M
순이익/손실:
$-6.38M
주가수익비율:
-16.73
EPS:
-1.2009
순현금흐름:
$-39.84M
1주 성능:
-14.62%
1개월 성능:
-21.15%
6개월 성능:
-31.48%
1년 성능:
-30.91%
1일 변동 폭
$19.94
$20.63
1주일 범위
$19.94
$23.83
52주 변동 폭
$19.94
$39.70
Assembly Biosciences Inc Stock (ASMB) Company Profile
명칭
Assembly Biosciences Inc
전화
(833) 409-4583
주소
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
20.09 | 409.04M | 71.10M | -6.38M | -39.84M | -1.2009 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-01 | 개시 | UBS | Buy |
| 2025-09-24 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-08-18 | 재개 | H.C. Wainwright | Buy |
| 2025-03-25 | 개시 | Guggenheim | Buy |
| 2024-09-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-13 | 개시 | H.C. Wainwright | Neutral |
| 2021-09-02 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-03-23 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-10-19 | 개시 | Truist | Buy |
| 2019-10-16 | 개시 | Mizuho | Buy |
| 2018-11-19 | 개시 | Leerink Partners | Outperform |
| 2018-10-08 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-08-08 | 개시 | Robert W. Baird | Outperform |
| 2018-04-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Neutral |
| 2017-11-08 | 개시 | Jefferies | Buy |
| 2017-05-30 | 개시 | Chardan Capital Markets | Buy |
모두보기
Assembly Biosciences Inc 주식(ASMB)의 최신 뉴스
Assembly Biosciences to present ABI-6250 phase 1a data at AASLD By Investing.com - Investing.com South Africa
Assembly Biosciences, Inc. Presents Positive Phase 1a Safety, Tolerability And Target Engagement Data For ABI-6250 At AASLD The Liver Meeting - www.marketscreener.com
Assembly Biosciences Plans to Present Posters Featuring New Phase 1a Data From ABI-6250 Program - Yahoo Finance
Assembly Biosciences to present ABI-6250 phase 1a data at AASLD - Investing.com
Assembly Biosciences, Inc. (ASMB) stock price, news, quote and history - Yahoo Finance Australia
Assembly Biosciences Announces Two Phase 1a ABI-6250 Posters to Be Presented at The Liver Meeting 2026 - Quiver Quantitative
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026 - The Manila Times
EBITDA per share of Assembly Biosciences, Inc. – HAN:V7B - TradingView
Diluted net income available to common stockholders of Assembly Biosciences, Inc. – HAN:V7B - TradingView
Equity in earnings of Assembly Biosciences, Inc. – HAN:V7B - TradingView
Assembly Biosciences, Inc. Actuals & Estimates (HAN:V7B) - TradingView
V7B Forecast — Price Target — Prediction for 2027 - TradingView
Assembly Biosciences (Nasdaq:ASMB)Stock Analysis - Simply Wall Street
Assembly Biosciences, Inc.(NasdaqGS:ASMB) added to S&P Biotechnology Select Industry Index - marketscreener.com
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference - The Manila Times
Assembly Bio schedules a live webcast for Sept. 16 - Stock Titan
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks - TradingView
Why is Assembly Biosciences stock surging today? By Investing.com - Investing.com Australia
Assembly Bio opts into 40% U.S. profit share for herpes drug By Investing.com - Investing.com South Africa
Why is Assembly Biosciences stock surging today? - Investing.com
Why is Assembly Biosciences stock surging today? By Investing.com - Investing.com Canada
Assembly Biosciences (ASMB) Shares U.S. Development Costs and Profits with Gilead on Herpes Treatment - GuruFocus
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com South Africa
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com Nigeria
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com India
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com Canada
Assembly Bio stock gains after exercising Gilead profit option - investing.com
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com UK
Assembly Bio stock gains after exercising Gilead profit option - Investing.com
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program - The Manila Times
Assembly Bio opts into 40% U.S. profit share for herpes drug - Investing.com Canada
Assembly Bio opts into 40% U.S. profit share for herpes drug By Investing.com - Investing.com India
Assembly Biosciences exercises profit share option with Gilead for HSV program - TipRanks
Assembly Bio opts into 40% U.S. profit share for herpes drug - Investing.com UK
A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. - Stock Titan
Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services - Yahoo Finance
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High? - Yahoo Finance
Should You Buy Assembly Biosciences (ASMB) After Golden Cross? - Yahoo Finance
How Assembly Biosciences Inc. (ASMB) Affects Rotational Strategy Timing - Stock Traders Daily
Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Assembly Biosciences (ASMB) - The Globe and Mail
ASMB Maintained by Mizuho -- Price Target Lowered to $45 - GuruFocus
ASMB Initiates Coverage On UBS -- Price Target Announced at $52. - GuruFocus
Assembly Biosciences Price Target Announced at $52.00/Share by UBS - Moomoo
Assembly Biosciences price target raised to $53 from $45 at Mizuho - TipRanks
UBS initiates Assembly Biosciences stock with buy rating on antiviral platform - Investing.com Nigeria
UBS initiates Assembly Biosciences stock with buy rating on antiviral platform - Investing.com
UBS initiates Assembly Biosciences stock with buy rating on antiviral platform By Investing.com - Investing.com South Africa
UBS initiates Assembly Biosciences stock with buy rating on antiviral platform - Investing.com UK
Mizuho lowers Assembly Biosciences stock price target to $45 - Investing.com
Assembly Biosciences Inc (ASMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Assembly Biosciences Inc 주식 (ASMB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bjorkquist Jeanette M | PFO and PAO |
Mar 30 '26 |
Sale |
26.69 |
328 |
8,755 |
11,089 |
| White Nicole S | Chief Manufacturing Officer |
Mar 30 '26 |
Sale |
26.69 |
197 |
5,258 |
37,477 |
4.22%
자본화:
|
볼륨(24시간):